Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease

National Medical Journal of China

Volumn 91, Issue 5, 2011, Pages 301-303

  Li, Wei ^a   Zhao, Jian Hua ^a   Sun, Sheng Gang ^b   Zhang, Jie Wen ^a   Suo, Ai Qin ^a   Ma, Ming Ming ^a  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b NONE

Author keywords

Cognitive impairment; Dementia; Memantine; Movement disorders; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; MEMANTINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; TREATMENT DURATION; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84869814587     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2011.05.004     Document Type: Article

References (13)

1. Salawu FK, Danburam A, Olokoba AB. Non-motor symptoms of Parkinson's disease: diagnosis and management. Niger J Med, 2010, 19: 126-131.
2. Weintraub D, Stern MB. Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry, 2005, 13: 844-851.
3. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med, 2004, 351: 2509-2518.
4. 2006, 9: 742-744.
5. McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol, 2004, 3: 19-28.
6. Braak H, Del Tredici K. Pathophysiology of sporadic Parkinson's disease. Fortschr Neurol Psychiatr, 2010, 78 Suppl 1: S2-4.
7. Bruck A, Kurki T, Kaasinen V, et al. Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. J Neurol Neurosurg Psychiatr, 2004, 75: 1467-1469.
8. Jokinen P, Bruck A, Aalto S, et al. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord, 2009, 15: 88-93.
9. Francis PT, Perry EK. Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov Disord, 2007, 22 Suppl 17: S351-357.
10. Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer's disease and other neurodegenerative disorders-memantine, a new hope. Pharmacol Res, 2005, 51: 1-17.
11. Piccirillo G, Fimognari FL, Viola E, et al. Age-adjusted normal confidence intervals for heart rate variability in healthy subjects during head-up tilt. Int J Cardiol, 1995, 50: 117-124.
12. Varanese S, Howard J, Di Rocco A. NMD A antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease. Mov Disord, 2010, 25; 508-510.
13. Wenk GL, Parsons CG, Danysz W. Potential role of N-methyl-D- aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol, 2006, 17: 411-424.